SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Lili Boulanger

PatientLili Boulanger
Date of birth2004-08-21
IdentifiersMRN HR-ET025-SYN; SSN (made up) 000-25-7731
Document date2026-03-02
AuthorOdile Marchetti-Rowe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review at week 4 of risankizumab, on the day of the second infusion. [S]

History of Present Illness

Ms. Boulanger had her first risankizumab infusion and intravenous iron four weeks ago without reaction and has her second infusion today. Her stools are down to two or three a day, soft, with no night-time stool, and the cramps are mild (Harvey-Bradshaw Index 5). She is on 20 mg of prednisone, falling to 15 mg this week, and has noticed a rounder face and lighter sleep. She has gained 1.6 kg with the supplements. The mycobacterial culture from her biopsies shows no growth after five weeks; the final report is due next week. She is rehearsing for her concert at the end of the month and composing most mornings. [S]

ElementDetail
Interval changeRisankizumab dose 1 and iron infusion four weeks ago; dose 2 today
ActivityHarvey-Bradshaw Index 5, down from 11
Prednisone20 mg, tapering as planned; mild sleep disturbance
TuberculosisMycobacterial culture: no growth at five weeks
WorkRehearsing for the March concert

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; energy improving
GastrointestinalPositiveTwo or three soft stools a day; mild cramps; no blood
IntegumentaryNegativeNo rash; no yellowing of the skin
EndocrinePositiveRounder face on prednisone; no excessive thirst
PsychiatricPositiveLighter sleep on prednisone; mood better; PHQ-9 5, GAD-7 6

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugsOne or two tablets up to every 6 hours as neededOral route2025-12-15activeS
Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect40 mg each morning, tapering by 5 mg weeklyOral route2026-01-28 to 2026-03-24completedS
Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction)One infusion every 4 weeks for three dosesIntravenous route2026-02-02 to 2026-04-26completedS
Ferric derisomaltose 1000 mg in 10 mL intravenous infusion, single doseSingle infusionIntravenous route2026-02-02 to 2026-02-02completedS
Cholecalciferol (vitamin D3) 2000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-01-28activeS
Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisoneOne tablet daily with foodOral route2026-01-28 to 2026-03-24completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-02Body height160cmS
2026-03-02Body weight46.4kgS
2026-03-02Body mass index (BMI) [Ratio]18.1kg/m2S
2026-03-02Systolic blood pressure108mm[Hg]S
2026-03-02Diastolic blood pressure68mm[Hg]S
2026-03-02Heart rate84/minS
2026-03-02Respiratory rate14/minS
2026-03-02Body temperature36.8CelS
2026-03-02Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-02Hemoglobin [Mass/volume] in Blood11.6g/dL12-15.5 g/dLLowS
2026-03-02C reactive protein [Mass/volume] in Serum or Plasma8mg/L<=5 mg/LHighS
2026-03-02Albumin [Mass/volume] in Serum or Plasma3.7g/dL3.5-5 g/dLNormalS
2026-03-02Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L<=33 U/LNormalS
2026-03-02Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L<=32 U/LNormalS
2026-03-02Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL<=1.2 mg/dLNormalS
2026-03-02Phosphate [Mass/volume] in Serum or Plasma3mg/dL2.5-4.5 mg/dLNormalS
2026-03-02Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-03-02Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S

Physical Exam

Vital signs recorded on 2026-03-02; see the Vital Signs section. [S]

SystemFinding
GeneralBrighter; BMI 18.1
EyesNo jaundice
MouthAphthous ulcers healed
AbdomenMild right lower quadrant tenderness; no fullness

Problems

ProblemClinical statusVerificationCodeProvenance
Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settledactiveconfirmed K50.80S — Synthetic diagnosis confirmed within the modern episode; her historical illness is documented (D), but whether it was intestinal tuberculosis or Crohn disease remains a retrospective interpretation (R) and is disputed.
Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging bookedresolvedconfirmed R19.7S — Synthetic presenting concern at the index visit, superseded by the diagnosis; the documented symptoms of early 1915 are echoed (D).
Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9)activeconfirmed D50.0S — Synthetic finding at presentation; corrected by intravenous iron.
Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dLactiveconfirmed E44.0S — Synthetic nutritional status at presentation; resolved with treatment and dietitian support.
Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL)activeconfirmed E55.9S — Synthetic finding at presentation.
Long-term use of risankizumab, an immunosuppressive biologic, for Crohn diseaseactiveconfirmed Z79.620S — Synthetic treatment status.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptoms and Harvey-Bradshaw IndexEvery visitCompleted today5, down from 11 (clinical response)
LaboratoryCRPEvery visit during inductionCompleted today8 mg/L, down from 38
LaboratoryLiver enzymes and bilirubin during risankizumab inductionThrough at least week 12Completed todayALT 22, AST 24, bilirubin 0.5
LaboratoryHemoglobin and phosphate after intravenous ironFour weeks after the infusionCompleted todayHemoglobin 11.6 g/dL; phosphate 3.0 mg/dL
LaboratoryAlbumin and weightEvery visitCompleted todayAlbumin 3.7 g/dL; weight up 1.6 kg
LaboratoryMycobacterial culture of the biopsiesFinal result at six to eight weeksUp to dateNo growth at five weeks; final report next week
LaboratoryHepatitis B antibody after the boosterOne to two months after the doseDeferredNot drawn today, a deviation from the plan: it was left off the order with the infusion blood tests. Rescheduled with the week-12 tests. She has no known exposure and the booster was given, so harm is unlikely; standing orders for post-vaccine antibody checks are now added at the time of the dose
Medication safetyCorticosteroid side effects and taperEvery visit on steroidsCompleted todayMild sleep disturbance and facial rounding; taper on schedule
SurveyDepression and anxiety screen (PHQ-9 and GAD-7)At intervalsCompleted todayPHQ-9 5 and GAD-7 6
LaboratoryFecal calprotectinAbout three months after starting treatmentDueAt week 12
ImagingIleocolonoscopy for endoscopic responseSix to twelve months after starting treatmentDueIn the autumn

Goal progress:

Guideline basis: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025); STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the IOIBD. Gastroenterology 2021;160:1570-1583 (2021); SKYRIZI (risankizumab-rzaa): prescribing information (Crohn disease dosing; hepatotoxicity monitoring; tuberculosis evaluation; immunizations) (2026)

Follow-up: Third infusion at week 8. Review at week 12, the first maintenance dose. Next scheduled visit 2026-04-27: review at week 12, the first maintenance dose of risankizumab. [S]